Proactive Investors - Futura Medical PLC has announced the UK launch of its groundbreaking erectile dysfunction (ED) treatment gel, Eroxon, hailing the event as a 'significant milestone'.
Futura's transdermal drug delivery technology has been used to develop a fast-acting topical gel with minimal side effects. It offers an alternative to existing ED treatments without the side effects of the current 'blue pill' treatments.
Eroxon is the first pan-European topical treatment for ED available without a doctor's prescription and can be purchased over the counter. James
Futura's UK and EU distribution partner, Cooper Consumer Health, has confirmed the product is now available from boots.com and will be rolled out in stores starting Tuesday (April 18).
Chief executive James Barder said: "This is a significant milestone for the company as our distribution partners continue to increase the availability of Eroxon across different markets.
"ED is a growing problem, and we believe that today's announcement will be welcomed by many men suffering from ED for whom current front-line treatments for ED are unsuitable."
ED affects at least one in five men globally, with a growing number of men under the age of 40 being diagnosed with the condition.
Factors contributing to this issue include an ageing population, increased obesity, health conditions like diabetes, societal pressures, and "performance anxiety" in younger men.